Comparison and significance of specific and non-specific cellular immunity in patients with chronic hepatitis B caused by infection with genotypes B or C of hepatitis B virus

Gu, Xing; Yang, Xiao; Wang, Dong; Wu, Hai-Liang; Chen, HaoKun; Xu, Yingkun; Lu, Zhiyan

doi:10.1007/s11427-009-0098-0

Cited by 8 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the initial non-specific immunity response to the HBV virus, specific immunity plays a critical role in fighting against the surviving virus18. T lymphocytes are important effector cells in specific immune response and following stimulation of HBV antigens, T cells are classified as killer T cells [mainly CD8+ cytotoxic T lymphocytes (CTLs)] and helper T lymphocytes (Th).…”

Section: Discussionmentioning

confidence: 99%

Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment

Guo

Mao

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to determine the correlation between dynamic changes in serum cytokine/chemokine expression levels in response to entecavir (ETV) treatment and HBV e antigen (HBeAg) seroconversion in patients with chronic hepatitis B (CHB). Four cytokines (interleukin [IL]-4, IL-6, IL-8, and interferon-γ) and five chemokines (macro-phage inflammatory protein [MIP]-1α, MIP-1β, platelet derived growth factor-BB, and interferon-inducible protein 10 [IP-10]) before ETV therapy and at 3, 6, 12, 24, 36 and 60 months during therapy in 105 CHB patients were analyzed. The results showed that the low decrease rate of IP-10 levels after 1 year of ETV treatment was an independent predictor of HBeAg seroconversion at year 5 (Hazard ratio = 0.972). The area under the receiver operating characteristic curves for the decrease rate of IP-10 levels after 1 year of treatment to discriminate a year-5 HBeAg seroconversion was 0.752 (p = 0.005). The results indicate that higher IP-10 level at year one of ETV treatment is associated with an increased probability of HBeAg seroconversion. Quantification of IP-10 during ETV treatment may help to predict long-term HBeAg seroconversion in patients with CHB.

show abstract

Section: Discussionmentioning

confidence: 99%

Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment

Guo

Mao

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In the process of clearing the virus by specific T cells, the noncytolytic route may play a more important role (11). Nonspecific cellular immunity is relatively weak in clearing HBV, but it may cause liver cell injuries in the process (12)(13)(14). Thus, we studied the changes in HBV-specific and nonspecific cellular immune responses before and after CHB progressed to chronic severe hepatitis B to provide evidence for the rational treatment, control, and prevention of deterioration of CHB.…”

Section: Discussionmentioning

confidence: 99%

Alteration in Cellular Immunity after Chronic Hepatitis B Deteriorated into Severe Hepatitis and Its Significance

Gu¹,

Xiao

et al. 2011

Hpat Mon

View full text Add to dashboard Cite

Implication for health policy/practice/research/medical education:To predict at certain degree if chronic hepatitis B will develop into severe hepatitis by testing cellular immunity at early stage , provide lab basis to prevent or stop the progress of chronic hepatitis B developing into severe hepatitis. ObjectivesThe pathogenesis of hepatitis B is associated with cellular immune responses that aim to remove HBV from the body (1). If the resulting cellular immunity is too intensive, it can result in the necrosis of many liver cells and severe hepatitis. However, it is unknown whether HBV-specific or nonspecific cellular immune responses immediate the deterioration of CHB. Patients and Methods SubjectsWe enrolled 255 CHB patients into this study from BackgroundClinically, liver disease can progress into chronic severe hepatitis B in some patients with CHB, even after admission and after receiving treatment. It is difficult to predict which CHB patients will develop chronic severe hepatitis.Background: It is difficult to predict what type of chronic hepatitis B (CHB) progresses to chronic severe hepatitis B.Objectives: This study aimed to observe changes in the HBV-specific and -nonspecific cellmediated immune responses after CHB deteriorates into severe hepatic disease and explore the significance of such changes. Patients and Methods:This study aimed to observe changes in the HBV-specific and -nonspecific cell-mediated immune responses after CHB deteriorates into severe hepatic disease and explore the significance of such changes. Results: In 49 of 255 CHB patients (19.22%), the disease developed into chronic severe hepatitis (early stage) an average of 10.06 ± 1.73 days after admission. CD4+ and NK cells levels in Group A were lower after progression into severe hepatitis than on the second day of admission (baseline) (P < 0.01). CD8 + cells and nonspecific CTL levels in Group A were higher after progression than at baseline (P < 0.01), and latter was higher than in Group B at baseline (P < 0.01); the levels of CD8 + cells and nonspecific CTLs in Group A after progression were significantly higher than those of Group B 10 days after admission (P < 0.01). There were no significant differences in HBV-specific CTL levels in Group A before and after progression to severe hepatitis (P > 0.05). Conclusions: Our results suggest that the immunological pathogenesis of chronic severe hepatitis B is related to significant rises in CD8 + and nonspecific CTL levels and that such increases predict that the disease will deteriorate into severe hepatitis.

show abstract

“…Therefore, the T cell immune response induced during HBV infection of both genotypes is consistent. Considering the most common HBV genotype infected in Chinese patients are C or B and infected with genotype C HBV will lead to more severe liver damages [ 43 ], we used the C genotype HBV plasmid to mimick HBV re-exposure, while the transgenic mice were integrated with genotype D HBV. Also, we compared the amino acid sequence between the small HBsAg of genotype C strain and D strain used in this study (data not shown) and found that most CD8 + T cell epitopes and “a” determinant region were highly conserved between these two strains.…”

Section: Discussionmentioning

confidence: 99%

Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups

Ning

Wang

Zheng

et al. 2022

Emerging Microbes & Infections

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection due to perinatal mother-to-infant transmission (MTIT) remains a serious global public health problem. It has been shown that intrauterine exposure to HBV antigens might account for the MTIT-related chronic infection. However, whether hepatitis B surface antigen (HBsAg) intrauterine exposure affected the offspring’s immune response against HBV and MTIT of HBV has not been fully clarified. In this study, we investigated the effects and the potential mechanisms of the HBsAg intrauterine exposure on the persistence of HBV replication using a solely HBsAg intrauterine exposure mice model. Our results revealed that solely HBsAg intrauterine exposure significantly accelerated the clearance of HBV when these mice were hydrodynamically injected with pBB4.5-HBV1.2 plasmids after birth, which may be due to the increased number of HBs-specific CD8 + T cells and interferon-gamma secretion in the liver of mice. Mechanismly, HBsAg intrauterine exposure activated antigen-presenting dendritic cells, which led to the generation of antigen-specific cellular immunological memory. Our data provide an important experimental evidence for the activation of neonatal immune response by HBsAg intrauterine exposure.

show abstract

Comparison and significance of specific and non-specific cellular immunity in patients with chronic hepatitis B caused by infection with genotypes B or C of hepatitis B virus

Cited by 8 publications

References 6 publications

Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment

Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment

Alteration in Cellular Immunity after Chronic Hepatitis B Deteriorated into Severe Hepatitis and Its Significance

Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups

Contact Info

Product

Resources

About